drugset / Trial / NCT00655369

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

NCT00655369 ↗

Phase 2 Completed 306 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In a Phase II trial in subjects with nonrestorative sleep, PD 0200390 demonstrated a positive treatment effect relative to placebo on the primary endpoint, the weekly version of the Restorative Sleep Questionnaire (RSQ-W). In this study, the dose-response relationship of varying doses of PD 0200390 using the Restorative Sleep Questionnaire (RSQ-W), will be explored in Nonrestorative Sleep subjects.

Timeline

Start
2008-04
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ATAGABALIN Small molecule 5 mg Oral
Subject ATAGABALIN Small molecule 15 mg Oral
Subject ATAGABALIN Small molecule 25 mg Oral
Subject ATAGABALIN Small molecule 35 mg Oral
Subject ATAGABALIN Small molecule 50 mg Oral

Indications